麦角新碱超声心动图对冠状动脉痉挛无创诊断的诊断与预后价值
该研究分析韩国3家三级转诊医院14012例接受麦角新碱超声心动图患者的临床数据,阳性率15.3%,无检查相关死亡或心肌梗死;中位随访11.4年显示阳性患者10年总生存率和心血管无死亡生存率均更低,阳性为全因死亡和心血管死亡的独立危险因素。
要点
- 麦角新碱超声心动图阳性率15.3%,不同诊断间频率各异,急性冠脉综合征38.2%、变异型心绞痛31.8%。
- 检查安全性好,0.4%提前终止,无死亡或心肌梗死发生。
- 阳性患者10年总生存率96.7% vs 91.5%、心血管无死亡生存率99.2% vs 96.7%,均更低。
关键影像表现/征象
- 麦角新碱超声心动图通过超声监测心室壁运动进行非侵入性激发试验。
- 阳性结果定义为激发试验中出现室壁运动异常,阳性率15.3%(2144例)。
- 不同诊断的阳性频率:急性冠脉综合征38.2%、变异型心绞痛31.8%、劳力性心绞痛14.9%、流产型心脏性猝死17.6%、晕厥9.9%。
诊断标准与关键数值
- 阳性标准为麦角新碱激发后超声心动图监测到室壁运动异常。
- 阳性患者10年总生存率96.7±0.2% vs 阴性患者91.5±0.6%(p<0.0001),阳性更低。
- 阳性患者10年心血管无死亡生存率99.2±0.1% vs 阴性患者96.7±0.4%(p<0.0001),阳性更低。
- 校正年龄和男性后,阳性为全因死亡的独立危险因素(HR 1.879,95%CI 1.548-2.280;p<0.001)。
- 校正年龄和男性后,阳性为心血管死亡的独立危险因素(HR 2.903,95%CI 2.061-4.089;p<0.001)。
临床应用与阅片要点
- 麦角新碱超声心动图可用于冠状动脉痉挛的无创诊断,即使无血管造影证实的固定冠状动脉狭窄,取决于临床表现。
- 作者认为麦角新碱超声心动图可替代侵入性痉挛激发试验。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: This study sought to obtain large-scale evidence supporting the clinical usefulness of ergonovine echocardiography.
BACKGROUND: The role of noninvasive ergonovine provocation testing with echocardiographic monitoring of ventricular wall motion (ergonovine echocardiography) needs to be defined.
METHODS: Clinical data of patients who underwent ergonovine echocardiography in 3 tertiary referral hospitals in South Korea were analyzed.
RESULTS: Ergonovine echocardiography was performed in 14,012 patients (mean age 52.8 ± 11.1 years; 6,213 [44.3%] women) after exclusion of significant coronary arterial stenosis by functional (treadmill or perfusion scan, n = 9,824) or anatomic test (invasive or computerized tomographic coronary angiography, n = 4,188). Premature termination developed in 0.4% (n = 51), and a positive result was observed in 2,144 patients (15.3%), with variable frequencies according to the diagnosis (acute coronary syndrome [38.2%], variant angina [31.8%], effort angina [14.9%], aborted sudden cardiac death [17.6%], syncope [9.9%]). There was no mortality or development of myocardial infarction during the test. During median follow-up of 11.4 (interquartile range: 7.2 to 15.8) years, death of any cause and cardiovascular death occurred in 494 and 143 patients, respectively. The 10-year overall (96.7 ± 0.2% vs. 91.5 ± 0.6%; p < 0.0001) and cardiovascular mortality-free (99.2 ± 0.1% vs. 96.7 ± 0.4%; p < 0.0001) survival rates were lower in patients with positive ergonovine echocardiography. Regarding patients with positive test results, the functional test group and the anatomic test group did not show a significant difference in the survival rates. After adjustment of age and male sex, a positive test was an independent risk factor associated with all-cause mortality (hazard ratio: 1.879, 95% confidence interval: 1.548 to 2.280; p < 0.001) and cardiovascular death (hazard ratio: 2.903, 95% confidence interval: 2.061 to 4.089; p < 0.001).
CONCLUSIONS: Ergonovine echocardiography for coronary vasospasm diagnosis could be safely performed even without angiographic documentation of fixed coronary stenosis depending on the clinical presentation, and provided important prognostic implication. Ergonovine echocardiography can replace the invasive spasm provocation testing, which has been overlooked unfairly.
引用
- Om SY, Yoo SY, Cho GY, et al. Diagnostic and Prognostic Value of Ergonovine Echocardiography for Noninvasive Diagnosis of Coronary Vasospasm. JACC Cardiovasc Imaging. 2020. PMID: 32417336. doi:10.1016/j.jcmg.2020.03.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。